Tandem Diabetes Care, Inc. (TNDM) Can’t Be More Hot. Just Reaches 52-Week High

July 13, 2018 - By Sonya McDaniel

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Logo

The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) hit a new 52-week high and has $28.25 target or 9.00 % above today’s $25.92 share price. The 6 months bullish chart indicates low risk for the $1.30B company. The 1-year high was reported on Jul, 13 by Barchart.com. If the $28.25 price target is reached, the company will be worth $116.82M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.85% or $0.47 during the last trading session, reaching $25.92. About 1.37M shares traded. Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has risen 73.21% since July 13, 2017 and is uptrending. It has outperformed by 60.64% the S&P500.

Analysts await Tandem Diabetes Care, Inc. (NASDAQ:TNDM) to report earnings on July, 26. They expect $-0.35 EPS, up 92.05 % or $4.05 from last year’s $-4.4 per share. After $-1.03 actual EPS reported by Tandem Diabetes Care, Inc. for the previous quarter, Wall Street now forecasts -66.02 % EPS growth.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Ratings Coverage

Among 6 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Tandem Diabetes Care has $30 highest and $4.0 lowest target. $11.63’s average target is -55.13% below currents $25.92 stock price. Tandem Diabetes Care had 7 analyst reports since February 27, 2018 according to SRatingsIntel. The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) earned “Overweight” rating by PiperJaffray on Monday, May 14. The company was maintained on Friday, March 2 by Stifel Nicolaus. The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) earned “Hold” rating by Cowen & Co on Tuesday, February 27. As per Friday, March 23, the company rating was upgraded by Robert W. Baird. Cowen & Co upgraded the stock to “Buy” rating in Wednesday, March 28 report.

More notable recent Tandem Diabetes Care, Inc. (NASDAQ:TNDM) news were published by: Nasdaq.com which released: “Mid-Afternoon Market Update: Red Hat Falls On Weak Forecast; Tandem Diabetes Care Shares Climb” on June 22, 2018, also Fool.com with their article: “2 Stocks That Turned $1000 Into More Than $8000 This Year” published on July 10, 2018, Fool.com published: “Tandem Diabetes Takes Aim at Medtronic’s Artificial Pancreas” on June 24, 2018. More interesting news about Tandem Diabetes Care, Inc. (NASDAQ:TNDM) were released by: Seekingalpha.com and their article: “Oppenheimer updates on Tandem Diabetes Care” published on June 22, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Crude Oil Up Over 4%; WillScot Shares Spike Higher” with publication date: June 22, 2018.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company has market cap of $1.30 billion. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It currently has negative earnings. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.